Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15

被引:75
作者
Manabe, Atsushi [1 ]
Ohara, Akira [2 ]
Hasegawa, Daisuke [1 ]
Koh, Katsuyoshi [3 ]
Saito, Tomohiro [4 ]
Kiyokawa, Nobutaka [5 ]
Kikuchi, Akira [6 ]
Takahashi, Hiroyuki [7 ]
Ikuta, Koichiro [8 ]
Hayashi, Yasuhide [9 ]
Hanada, Ryoji [6 ]
Tsuchida, Masahiro [10 ]
机构
[1] St Lukes Int Hosp, Dept Pediat, Tokyo Childrens Canc Study Grp, Chuo Ku, Tokyo 1048560, Japan
[2] Toho Univ, Dept Pediat 1, Tokyo, Japan
[3] Toho Univ, Dept Pediat, Tokyo, Japan
[4] Natl Res Inst Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan
[5] Natl Res Inst Child Hlth & Dev, Dept Dev Biol, Tokyo, Japan
[6] Saitama Childrens Med Ctr, Dept Hematol Oncol, Iwatsuki, Saitama, Japan
[7] Saitama Childrens Med Ctr, Dept Hematol Oncol, Iwatsuki, Saitama, Japan
[8] Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa 232, Japan
[9] Gunma Childrens Med Ctr, Dept Hematol Oncol, Shibukawa, Japan
[10] Ibaraki Childrens Hosp, Dept Pediat, Mito, Ibaraki, Japan
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷 / 08期
关键词
lymphoblastic leukemia; children; clearance of blasts; steroid response;
D O I
10.3324/haematol.12365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Treatment response has become one of the most important prognostic factors in childhood acute lymphoblastic leukemia. We evaluated the significance of the complete clearance of peripheral leukemic blasts on survival in children with acute lymphoblastic leukemia. Design and Methods Seven hundred and fifty-four children diagnosed with acute lymphoblastic leukemia, consecutively enrolled from 1999 to 2003 in the TCCSG L99-15 study, were eligible for analysis. Patients were stratified into three risk groups based on presenting features, such as age and the leukocyte count before starting the treatment, followed by reclassification into three categories 7 days after prednisolone monotherapy based on the peripheral blast count; 0/mu L (Day8NoBlasts), 1-999/mu L and >= 1,000/mu L. Results After 7 days of prednisolone monotherapy, 249 patients (33%) were classified as Day8NoBlasts, 392 patients (52%) had blast counts of 1-999/mu L, and 113 patients (15%) had blast counts >= 1,000/mu L. The event-free survival for all patients was 79.6 +/- 1.6 (SE)% at 4 years, whereas that for patients with Day8NoBlasts was 90.4 +/- 2.0% (n=249) and the event-free survival for the other patients was 74.2 +/- 2.2% (n=504) (log rank p < 0.001). The event-free survival for Day8NoBlasts patients with B-lineage acute lymphoblastic leukemia and T-cell acute lymphoblastic leukemia was 89.8 +/- 2.1% (n=226) and 95.7 +/- 4.3% (n=23), respectively. In a multivariate analysis, age at diagnosis, the initial white blood cell count, immunophenotype, and gender did not remain as independent risk factors for treatment failure, whereas Day8NoBlasts and marked hyperdiploidy (more than 50 chromosomes) became statistically significant. Conclusions Children with Day8NoBlasts constituted one third of all the cases with childhood acute lymphoblastic leukemia with an excellent outcome, and should be candidates for curative management with less intensive treatment.
引用
收藏
页码:1155 / 1160
页数:6
相关论文
共 22 条
[1]   Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II [J].
Aricò, M ;
Valsecchi, MG ;
Conter, V ;
Rizzari, C ;
Pession, A ;
Messina, C ;
Barisone, E ;
Poggi, V ;
De Rossi, G ;
Locatelli, F ;
Micalizzi, MC ;
Basso, G ;
Masera, G .
BLOOD, 2002, 100 (02) :420-426
[2]   Prognostic significance of minimal residual disease (MRD) in childhood B-precursor ALL and its relation to other risk factors. A Children's Oncology Group (COG) study. [J].
Borowitz, Michael J. ;
Devidas, Meenakshi ;
Bowman, W. Paul ;
Carroll, William L. ;
Chen, I. -Ming ;
Harvey, Richard ;
Hunger, Stephen ;
Martin, Paul L. ;
Pullen, Jeanette ;
Viswanatha, David ;
Willman, Cheryl L. ;
Winick, Naomi ;
Camitta, Bruce .
BLOOD, 2006, 108 (11) :69A-69A
[3]   Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia [J].
Dördelmann, M ;
Reiter, A ;
Borkhardt, A ;
Ludwig, WD ;
Götz, N ;
Viehmann, S ;
Gadner, H ;
Riehm, H ;
Schrappe, M .
BLOOD, 1999, 94 (04) :1209-1217
[4]   Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies:: results of a randomized European Organisation for Research and Treatment of Cancer -: Children's Leukemia Group phase 3 trial [J].
Duval, M ;
Suciu, S ;
Ferster, A ;
Rialland, X ;
Nelken, B ;
Lutz, P ;
Benoit, Y ;
Robert, A ;
Manel, AM ;
Vilmer, E ;
Otten, J ;
Philippe, N .
BLOOD, 2002, 99 (08) :2734-2739
[5]   Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia:: prognostic significance of CASP8AP2 [J].
Flotho, Christian ;
Coustan-Smith, Elaine ;
Pei, Deqing ;
Iwamoto, Shotaro ;
Song, Guangchun ;
Cheng, Cheng ;
Pui, Ching-Hon ;
Downing, James R. ;
Campana, Dario .
BLOOD, 2006, 108 (03) :1050-1057
[6]   PERSISTENCE OF CIRCULATING BLASTS AFTER 1 WEEK OF MULTIAGENT CHEMOTHERAPY CONFERS A POOR-PROGNOSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
GAJJAR, A ;
RIBEIRO, R ;
HANCOCK, ML ;
RIVERA, GK ;
MAHMOUD, H ;
SANDLUND, JT ;
CRIST, WM ;
PUI, CH .
BLOOD, 1995, 86 (04) :1292-1295
[7]   The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia [J].
Holleman, A ;
den Boer, ML ;
de Menezes, RX ;
Cheok, MH ;
Cheng, C ;
Kazemier, KM ;
Janka-Schaub, GE ;
Göbel, U ;
Graubner, UB ;
Evans, WE ;
Pieters, R .
BLOOD, 2006, 107 (02) :769-776
[8]   Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment [J].
Holleman, A ;
Cheok, MH ;
den Boer, ML ;
Yang, WJ ;
Veerman, AJP ;
Kazemier, KM ;
Pei, DQ ;
Cheng, C ;
Pui, CH ;
Relling, MV ;
Janka-Schaub, GE ;
Pieters, R ;
Evans, WE .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (06) :533-542
[9]   BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients:: results of DCLSG protocol ALL-8 (1991-1996) [J].
Kamps, WA ;
Bökkerink, JPM ;
Hakvoort-Cammel, FGAJ ;
Veerman, AJP ;
Weening, RS ;
van Wering, ER ;
van Weerden, JF ;
Hermans, J ;
Slater, R ;
van den Berg, E ;
Kroes, WG ;
van der Does-van den Berg, A .
LEUKEMIA, 2002, 16 (06) :1099-1111
[10]   Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter [J].
Lauten, M ;
Stanulla, M ;
Zimmermann, M ;
Welte, K ;
Riehm, H ;
Schrappe, M .
KLINISCHE PADIATRIE, 2001, 213 (04) :169-174